局所進行または転移性髄様甲状腺癌患者におけるバンデタニブ：無作為化二重盲検第III相試験

Wellsら（火曜）はこの問題を研究した。

www.synapsesocial.com/papers/69da2667a6045d71bfa3c3fc — DOI: https://doi.org/10.1200/jco.2011.35.5040

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer· 2010 · 516 citations
2. Somatic mutations in the <i>RET</i> proto‐oncogene in sporadic medullary thyroid carcinoma· 1996 · 278 citations
3. Regression Models and Life-Tables· 1992 · 26,652 citations
4. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients· 1998 · 569 citations
5. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A· 1993 · 1,960 citations